Alligator Bioscience

Rwanda
Byumba, Northern Province, Rwanda, 223 81

Company profile

Alligator Bioscience company profile

Alligator Bioscience is an innovative research based biotech company focused on developing novel drugs for immunotherapy of cancer. Alligator discovers and develops drug development candidates up to phase IIa clinical studies. Alligator’s pipeline currently counts three immune-modulating projects, ADC-1013, ADC-1015, and ADC-1016. Alligator uses its proprietary technology platforms: ALLIGATOR-GOLD, a unique fully human antibody library, and FIND® (Fragment INduced Diversity), a powerful in vitro based antibody optimization technology, in growing our pipeline.

Business identity

Contact email
[email protected]
Phone number
46 4 62 86 42 80
Operating status
Active
Company type
For Profit
Employee range
51-100 employees
Revenue range
$0-$1M
Founded
2000-01-01, Year

Headquarters

Postal code
223 81
Country code
RW
Continent
Africa

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
4
Total equity funding
$20.1M
Last funding
Post IPO Equity / $9.6M / 2025-12-01
Last equity funding
Post IPO Equity / $9.6M
Investors
3
Lead investors
1
Articles
223
Exited on
2016-11-23

Founders and investors

Lead investors

Fenja Capital

Investors

Fenja CapitalHome Capital ASMalmsten Invest